Deficiency of glycosaminoglycan (GAG) degradation causes a subclass of lysosomal storage disorders called mucopolysaccharidoses (MPSs), many of which present with severe neuropathology. Critical steps in the degradation of the GAG heparan sulfate remain enigmatic. Here we show that the lysosomal arylsulfatase G (ARSG) is the long-sought glucosamine-3-O-sulfatase required to complete the degradation of heparan sulfate. Arsg-deficient mice accumulate heparan sulfate in visceral organs and the central nervous system and develop neuronal cell death and behavioral deficits. This accumulated heparan sulfate exhibits unique nonreducing end structures with terminal N-sulfoglucosamine-3-O-sulfate residues, allowing diagnosis of the disorder. Recombinant human ARSG is able to cleave 3-O-sulfate groups from these residues as well as from an authentic 3-O-sulfated N-sulfoglucosamine standard. Our results demonstrate the key role of ARSG in heparan sulfate degradation and strongly suggest that ARSG deficiency represents a unique, as yet unknown form of MPS, which we term MPS IIIE.
L ysosomal storage disorders (LSDs) comprise a group of inherited metabolic diseases characterized by the accumulation of storage material reflecting a defect of a lysosomal hydrolase or associated protein (1) . Deficiencies in six lysosomal sulfatases lead to severe LSDs caused by accumulation of the corresponding sulfated substrate in the lysosome, resulting in the impairment of lysosomal function as well as the initiation of pathological cascades outside the lysosomes (1) (2) (3) . Arylsulfatase A (ARSA) cleaves sulfated galactosylceramides (4) , which, when absent, leads to metachromatic leukodystrophy (5) , whereas the other five characterized lysosomal sulfatases [arylsulfatase B, galactosamine-6-sulfatase, (N-acetyl)glucosamine-6-sulfatase, heparan-N-sulfatase (sulfamidase), and iduronate-2-sulfatase] function in the successive degradation of sulfated glycosaminoglycans (GAGs), namely heparan sulfate, chondroitin sulfate, dermatan sulfate, and keratan sulfate (3) . The lysosomal degradation of GAGs occurs stepwise beginning at the nonreducing end (NRE) of the sugar chain. Genetic deficiency of any of the enzymes involved leads to mucopolysaccharidoses (MPSs), a disease group comprising 11 disorders with distinct molecular defects (6) .
Among the degradation routes for the different GAGs, heparan sulfate catabolism is the most complex, involving three glycosidases, three known sulfatases, and one acetyltransferase (6) . Impairment of any of these enzymes has been linked to a specific form of MPS (MPS I, II, IIIA-D, and VII), all associated with severe neuropathology in affected patients because of massive storage of heparan sulfate (and also secondary metabolites) in the CNS (6) . However, the enzymatic removal of two low-abundance sulfate groups, namely 2-O-sulfate from glucuronic acid and 3-Osulfate from glucosamine, have remained enigmatic (7, 8) , and disorders in which the removal of these sulfate groups is defective have not been reported.
Arylsulfatase G (ARSG), a recently characterized lysosomal sulfatase with unknown physiological substrates (9) , has been reported previously to be associated with an adult form of ceroid lipofuscinosis in dogs (10) . In this study, we generated an ARSG-deficient mouse model by targeted disruption of the Arsg gene. In addition to heparan sulfate storage, we observed pathological changes common to MPStype LSDs and identified the physiological substrate of ARSG as the N-sulfoglucosamine-3-O-sulfate moiety of heparan sulfate. Our findings clearly demonstrate that ARSG is the long-sought glucosamine-3-sulfatase and that its deficiency results in a unique type of MPS, which we propose to designate as MPS IIIE (Sanfilippo E).
Results

ARSG-Deficient Mice Show Lysosomal Storage and Cellular Alterations
in the CNS. To determine the physiological function of ARSG, we inactivated the gene in mice by insertion of a neomycin-resistance cassette into exon 2 (Fig. S1A) . Arsg inactivation was confirmed by Southern blot analysis, genomic PCR, and RT-PCR (Fig. S1 B-D) . Arsg-knockout mice exhibited normal development, showed no obvious changes in appearance, and were fertile. Macroscopic inspection of organs was unremarkable. In the CNS, no apparent atrophy was evident up to the age of 12 mo; however, several neuronal and microglia populations revealed obvious vacuoles with prominent lysosomal storage pathology in Purkinje cells of the cerebellum and also in perivascular and meningeal macrophages ( Fig. 1 A and B and Fig. S2 A and B) . Thalamic and hippocampal neurons revealed sporadic lysosomal inclusions ( Fig. S2 C and D) . Storage vacuoles showed positive periodic acid-Schiff staining (Fig.  1C) and appeared partially empty after Epon embedding, indicating water-soluble carbohydrate storage material. Transmission electron microscopy (TEM) of the storage material in Purkinje cells showed lamellar to finely granular structures (Fig. 1D) . In older animals, storage material revealed autofluorescent properties at different excitation wavelengths ( Fig. 1 E and E′ and Fig. S2 E and E′). The autofluorescent material colocalized in ring-like structures with the lysosomal marker Lamp1 (Fig. 1 F and F′) . In the course of the disease, considerable loss of Purkinje cells was observed, becoming clearly evident at >10 mo ( Fig. 1 G and G′) . Neuronal cell death was accompanied by strong microgliosis (Fig. 1  H-I′) and astrogliosis in the cerebellar cortex ( Fig. 1 J and J′) . Behavioral Deficits. Behavioral assays revealed that Arsg-knockout mice did not differ from WT littermates in grip strength, rotarod test, or treadmill performance, indicating no obvious motor abnormalities up to the age of 12 mo. However, in the open-field test, 12-mo-old Arsg-deficient mice traveled significantly less distance in the center of the arena (F 1, 38 = 4.4; P < 0.05) (Fig. 1K ) and spent less time there (F 1, 38 = 5.7; P < 0.05) (Fig.  1L) . Notably, this progressive exploratory deficit appeared not to be due to overall reduced activity because total path length and center entries revealed no significant differences among the genotypes (Fig. S3 A and B) . Moreover, Arsg-deficient mice showed an age-dependent cognitive impairment, as could be observed in different learning tasks. From the age of 12 mo, they displayed significantly lower step-through latencies in the testing phase of the passive-avoidance task (F 1, 38 = 5.0; P < 0.05) (Fig.  1M) . Additionally, despite successful acquisition (Fig. S3C ), 12-mo-old Arsg-deficient mice spent less time in the target quadrant during the probe trial of the water-maze task (F 1, 38 = 4.4; P < 0.05) (Fig. 1N ). These analyses indicate that the oldest Arsgdeficient mice were not able to learn or to retain the spatial location of the platform as well as control mice, but were nevertheless still capable of mastering the task. Altogether, neuronal death and gliosis were accompanied by several behavioral deficits. The progressive course of these deficits with the micromorphological findings indicated manifestation of an LSD.
GAG Storage in Brain and Visceral Organs. Arsg-deficient mice exhibited obvious storage pathology not only in the CNS but also in several peripheral organs, including liver and kidney. Hepatocytes ( Fig. 2 A and A′) and hepatic sinusoidal endothelial cells ( Fig. 2 B and B′) showed accumulation of membrane-limited vacuoles filled with variable amounts of moderately or highly electron-dense and partially water-soluble material ( Fig. 2 C and C′). In the kidney, the epithelia of the thick ascending limb of Henle's loop and the collecting ducts showed prominent storage ( Fig. 2 D and D′). Because defects in five of the six other known lysosomal sulfatases result in lysosomal storage of undegraded GAGs (3) and become clinically evident as MPSs, we evaluated the potential of cuprolinic blue for staining of sulfated GAGs in the storage vacuoles in liver and kidney ( Fig. 2 E-F′). Prominent cuprolinic blue staining was observed in both organs, indicating strong accumulation of GAGs. Biochemical quantification revealed a striking increase of heparan sulfate in the knockouts, ∼10-fold in liver and ∼3-fold in kidney and brain compared with WT ( Fig. 2G) , clearly indicating an MPS-like storage disease. Chondroitin/dermatan sulfate was low in all tissues and did not accumulate except for a twofold increase in the liver of the knockouts (Fig. 2H ), which may reflect secondary storage induced by heparan sulfate accumulation, as reported for fibroblasts derived from MPS IIIA, IIIB, IIIC, and IIID patients (11) .
Storage Material Consists of Heparan Sulfate Chains with a Terminal 3-O-Sulfated Glucosamine. Heparan sulfate degradation proceeds sequentially from the NRE of the chain. Thus, if ARSG is involved in heparan sulfate catabolism, the NREs of stored heparan sulfate in the knockout tissues should contain carbohydrate determinants unique to the ARSG substrate. Heparan sulfate NREs were analyzed by using an adaptation of liquid chromatography/mass spectrometry (LC/MS) (12) . In this procedure, samples were depolymerized with bacterial lyases, and the products were derivatized with aniline. Heparan sulfate NREs are liberated as monosaccharides, disaccharides, and/or trisaccharides, depending on the structure of the termini (12) . Analysis of heparan sulfate from Arsg-deficient mouse tissues revealed unique NRE structures with masses consistent with a disulfated monosaccharide (dp1) and several trisaccharides (dp3) carrying two to four sulfate groups (Fig. 3A) . This pattern is similar but not identical to the pattern observed in heparan sulfate derived from MPS III cells and differs from the disaccharide NREs derived from other MPS disorders that affect processing of terminal uronic acids (12) . This finding indicates that heparan sulfate accumulating in Arsg-knockout tissues most likely terminates with a glucosamine residue containing one or more sulfate groups. Further analysis of NRE saccharides yielded the following information. First, the NRE monosaccharide comigrated with standard N-sulfoglucosamine-3-O-sulfate (GlcNS3S) (Fig. 3B) but not with standard N-sulfoglucosamine-6-O-sulfate (GlcNS6S) (Fig. 3C) . Second, the mass spectrum for the NRE monosaccharide contained a single primary ion with an m/z value of 415, consistent with a disulfated glucosamine residue (Fig. 3D) . Third, the storage NRE monosaccharide as well as the GlcNS3S standard did not form adduction ions with the ion-pairing agent dibutylamine (DBA) (Fig. 3E) . In contrast, GlcNS6S yielded both primary and adduction ions (Fig. 3F) . Fourth, tandem MS of the trisaccharide dp3(1Ac, 2S), i.e., carrying one acetyl and two sulfate groups, yielded daughter ions, confirming the presence of the disulfated glucosamine at the NRE terminus in the trisaccharide (Fig. S4A) . This dp3 differed from a dp3 biomarker present in heparan sulfate that accumulates in MPS IIIA cells (Fig. S4B) . Finally, treatment with propionic anhydride did not lead to a glucosamine N-acylation product, whereas an added unsubstituted glucosamine-containing disaccharide standard was acylated (Fig. S5) . Altogether, these findings strongly suggested that the terminus consists of a 3-O-sulfated N-sulfoglucosamine (GlcNS3S) unit.
ARSG Acts on GlcNS3S During Heparan Sulfate Degradation. To verify that GlcNS3S is the physiological substrate of ARSG, in vitro experiments with purified recombinant human ARSG (rhARSG) were performed. rhARSG released sulfate specifically from GlcNS3S but not from the monosulfated GlcNS or glucosamine-3-sulfate (GlcN3S) (Fig. 4A) . The recombinant human form of the closest homolog of ARSG, ARSA (rhARSA), acts on galactose 3-sulfate (4) but did not react with these substrates (Fig. 4A) . Activity of rhARSG toward its arylsulfate pseudosubstrate p-nitrocatechol sulfate (pNCS) (9) was also strongly inhibited by chemically synthesized GlcNS3S (Table  S1) . LC/MS analysis demonstrated that rhARSG treatment of GlcNS3S, but not of GlcNS6S, resulted in nearly complete conversion to the O-desulfated product GlcNS (Fig. 4 B and D) . No significant amount of N-desulfated product [GlcN3S or glucosamine-6-sulfate (GlcN6S)] was detected in any of the reactions. Finally, we demonstrated that the NRE of heparan sulfate storage material from lysosome-enriched fractions (tritosomes) isolated from Arsg-knockout liver is a substrate for this enzyme. Quantitative analysis by LC/MS of 250 pmol of heparan sulfate purified from Arsg-knockout liver yielded 18 pmol of GlcNS3S NRE monosaccharide (∼1 NRE/14 disaccharides). After in vitro treatment of heparan sulfate with rhARSG, less than 1 pmol of GlcNS3S NRE was detected (Fig. 4C) . Altogether, the data indicate that ARSG acts on terminal GlcNS3S residues in heparan sulfate to liberate the 3-O-sulfate group (Fig. 5) . 
Discussion
In this study, we demonstrate that lysosomal ARSG is a sulfatase specific for GlcNS3S residues at the NREs of heparan sulfate chains. ARSG is essential for the catabolism of heparan sulfate, as evidenced by the resulting heparan sulfate storage and MPS disease pathology in Arsg-deficient mice. Previous studies of Arsg-deficient dogs suggested that ARSG deficiency results in neuronal ceroid lipofuscinosis (NCL) (10), a type of LSD characterized by the nonspecific accumulation of autofluorescent ceroid lipopigments (13) . However, we believe that classification of ARSG deficiency as a form of NCL is incorrect because ARSG behaves as a lysosomal sulfatase (9), with no apparent similarities to any of the 10 known genes associated with NCL (3, 13) . Furthermore, with the exception of ARSA, which acts to degrade cerebroside 3-O-sulfate (sulfatide), all of the other five known lysosomal sulfatases degrade GAGs, and their deficiency causes MPS disease (3). Characterization of the NRE of stored heparan sulfate in the Arsg-deficient mouse, together with the demonstration that this diagnostic NRE is a specific substrate for the enzyme, now unambiguously characterizes ARSG deficiency as an MPS disorder. The accumulation of autofluorescent material, which was observed in Arsg-deficient dogs (10) as well as Arsg-deficient mice ( Fig. 1 E′ and F′) , likely results from secondary storage, which is observed in several LSDs (14) and in MPSs in particular (15, 16) . Glucosamine residues bearing 3-O-sulfate groups are relatively rare in heparan sulfate and are generated by members of the 3-O-sulfotransferase family of enzymes (17) . The rarity of this structure is likely to restrict severe storage to tissues that generate high levels of the 3-O-sulfated residues, which may explain why lysosomal storage in Arsg-knockout mice is less severe than that observed in mouse models for other MPS disorders characterized by deficiencies in enzymes that act on NRE glucosamine residues (12, 18) . Interestingly, rhARSG was unable to remove the 3-O-sulfate group from GlcN3S, which contains a free amino group (Fig. 4A) . There is evidence to suggest that GlcN3S can arise from the action of a subset of 3-O-sulfotransferases (19) (20) (21) , pointing to the possibility that another 3-Osulfatase may exist.
Before this study, there were four lysosomal enzymes known to be involved in processing of NRE glucosamine residues ( (6), which we recently showed to act preferentially on glucosamine-6-O-sulfate (12) . Patients lacking these enzymes have MPS type III disorders, which are subclassified as Sanfilippo diseases on the basis of their storage of heparan sulfate with a modified or unmodified glucosamine residue at the NRE as well as their pathological presentation (6) . ARSG also acts on a terminal glucosamine residue, and its deficiency results in the storage of heparan sulfate, causing neuropathology and behavioral defects characteristic of other Sanfilippo disease models (18, (22) (23) (24) (25) . Thus, we propose that ARSG deficiency defines a fifth type of Sanfilippo disease, which we propose be termed MPS IIIE. Importantly, both 3-O-sulfotransferases and ARSG are expressed in humans (9, 17) , indicating that, in addition to dogs and mice, human patients likely exist who suffer from ARSG deficiency. Hence, MPS-like patients with unclear etiology should be reanalyzed for ARSG deficiency.
In conclusion, ARSG is the missing N-sulfoglucosamine-3-Osulfatase and shows specificity for disulfated GlcNS3S as a substrate. ARSG thus acts at a critical step in lysosomal heparan sulfate degradation and is essential for catabolism to proceed past GlcNS3S residues, which are sequentially desulfated, first by the 3-O-sulfatase ARSG and then by sulfamidase (Fig. 5 ). The knockout mouse shows that deficiency of ARSG leads to a unique, as yet unknown type of MPS, which resembles the MPS IIIA-D syndromes and hence should be termed MPS IIIE.
Materials and Methods
Targeted Disruption of Murine Arsg, Genotyping, and Animal Breeding. The Arsg-knockout mouse strain was generated by targeted disruption of the murine Arsg gene, and Arsg deficiency was validated as described in detail in Fig. S1 and in SI Materials and Methods. The mice were kept under standard housing conditions. All animal experiments were performed in accordance with local guidelines and were approved by local authorities.
Behavioral Analysis. Behavioral analysis was performed as described (26) with minor modifications, including neuromotor testing (rotarod, grip strength, and treadmill performance), exploratory testing (open field), and tests for learning and memory (water maze and passive avoidance).
Histological Analysis. The tissues were prepared for histochemical and immunofluorescence staining by standard procedures. Tissue samples for TEM were prepared as described previously (27 shown at the glucuronic acid (third residue) is relatively rare, which agrees with the finding that no pentasulfated trisaccharides were found as NRE structures (Fig. 3A) . Scheme modified from Neufeld and Muenzer (6) according to findings from this work and from Lawrence et al. (12) . immunofluorescence were performed as described elsewhere (14) . Primary antibodies used were Lamp1 (Developmental Studies Hybridoma Bank), Calbindin (Sigma-Aldrich), CD68 (AbD Serotec), and GFAP (Sigma-Aldrich). Biotin-conjugated secondary antibodies were purchased from Vector Laboratories. Vectastain Elite Kit (Vector Laboratories) was used for signal amplification in immunohistochemistry, and 3,3′-diaminobenzidine tetrahydrochloride (Sigma-Aldrich) was used as substrate. Autofluorescence was detected with different wavelengths and filter settings. Cuprolinic blue staining was performed according to Scott (28 Enzyme Assays. Sulfate release assays were performed with 9 mU of rhARSG or rhARSA, expressed, and purified as described (9, 29) , and 500 μM GlcNS, GlcN3S (Sigma), or GlcNS3S (Dextra) in 500 mM sodium acetate (pH 5.6). Samples were incubated for 24 h at 37°C. Released sulfate was detected and quantified by turbidimetry using a published protocol (30) with minor modifications. Briefly, a 40 mM barium chloride solution in 15% PEG 6000 was prepared. Then, 50 mL of this solution was mixed with 60 μL of a 50 mM potassium sulfate solution, and 100 μL of this mixture was added to 200 μL of the sample. After 10 min of incubation at room temperature, followed by shaking for 30 s and an additional 30-s incubation step, turbidimetry was measured at 600 nm with a TECAN Infinite M200 microplate reader.
Lysosome Isolation from Mouse Liver (Tritosomes). Lysosome-enriched fractions from mouse liver were isolated with the nonionic detergent tyloxapol (Triton WR-1339) as described previously (31) .
GAG Purification. Arsg-knockout mice or WT animals at 12 mo of age were killed, and organs were removed and placed in ice-cold buffer [50 mM sodium acetate and 0.2 M NaCl (pH 6.0)]. After dissociation with a Polytron homogenizer, the resulting homogenates were digested on a shaker overnight at 37°C with 0.1 mg/mL Pronase and 0.1% Triton X-100. Samples were filtered through a 0.45-μm membrane, and GAGs were purified from cell homogenates by anion-exchange chromatography as described previously (32) . Briefly, 0.4 mL of diethylaminoethyl resin was washed with 20 column volumes of 50 mM sodium acetate buffer (pH 6) containing 0.2 M NaCl and 0.1% Triton X-100. After loading the samples, the column was washed with 40 column volumes of wash buffer, and GAGs were eluted with 5 column volumes of buffer containing 1 M NaCl. Samples were desalted by gel filtration (PD10), and samples were split in two for enzymatic depolymerization of heparan sulfate using 1 mU of each of heparin lyases I, II, and III or depolymerization of chondroitin/dermatan sulfate using 5 mU of chondroitinase ABC.
GAG Quantification and NRE Analysis. Depolymerized GAG preparations were derivatized by reductive amination with [ 12 C 6 ]aniline as previously described (33) . Each sample was mixed with commercially available standard unsaturated monosaccharides that were tagged with [ 13 C 6 ]aniline. Samples were analyzed by LC/MS using an LTQ Orbitrap Discovery electrospray ionization mass spectrometer (Thermo Scientific) equipped with quaternary HPLC pump (Surveyor MS Pump; Finnigan) and a C-18 reverse-phase microbore column as described previously (12) . DBA was used as ion-pairing reagent for LC/MS. The amount of heparan sulfate was standardized to the wet weight of processed tissue. NREs were identified on the basis of their unique mass as recently described (12) .
Statistical Analysis. Results are expressed as mean ± SEM or ± SD as stated. Differences between groups were examined for statistical significance by using unpaired Student's t test carried out with GraphPad Prism (GraphPad Software). In figures, asterisks indicate P values <0.05 (*) and <0.005 (**).
